Abstract | Chronic kidney disease (CKD) is prevalent in many countries, and the costs associated with the care of patients with end-stage renal disease (ESRD) are estimated to exceed US$1 trillion globally. The clinical and economic rationale for the design of timely and appropriate health system responses to limit the progression of CKD to ESRD is clear. Clinical care might improve if early-stage CKD with risk of progression to ESRD is differentiated from early-stage CKD that is unlikely to advance. The diagnostic tests that are currently used for CKD exhibit key limitations; therefore, additional research is required to increase awareness of the risk factors for CKD progression. Systems modelling can be used to evaluate the impact of different care models on CKD outcomes and costs. The US Indian Health Service has demonstrated that an integrated, system-wide approach can produce notable benefits on cardiovascular and renal health outcomes. Economic and clinical improvements might, therefore, be possible if CKD is reconceptualized as a part of primary care. This Review discusses which early CKD interventions are appropriate, the optimum time to provide clinical care, and the most suitable model of care to adopt.
Introduction
Chronic kidney disease (CKD) is a condition characterized by kidney damage and/or dysfunction, as well as an increased risk of cardiovascular disease.
1,2 Type 2 dia betes mellitus (T2DM) and hypertension cause up to twothirds of CKD; 3 less frequent causative factors include glomerulonephritis, nephrolithiasis and polycystic kidney disease. 4, 5 CKD is currently classified by measuring the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (Table 1) . Patients with an eGFR ≥60 ml/min/1.73 m 2 are assessed for typical markers of renal damage, such as abnormalities in urinary sediment or organ structure, to help confirm a diagnosis of CKD. 6 In a small proportion of cases, progressive CKD leads to end-stage renal disease (ESRD), where dialysis and/or kidney transplantation is essential for survival. The rate of CKD progression varies between patients, depending on the aetiology and pathology of the disease. 7, 8 CKD is prevalent in most high-income countries. 1, 7 The prevalence rate of CKD among non-institutionalized adults in the USA increased from 12.0% (95% CI, 10.4-13.5%) to 14.0% (95% CI, 12.4-15.7%) between the periods 1988-1994 and 1999-2004 . 9 Data obtained from [2007] [2008] [2009] [2010] [2011] [2012] suggest that this increase in prevalence has reached a plateau of 13.7% (95% CI, 12.1-15.2%). 9 Between 1999-2004 and 2007-2012, the prevalence of CKD stages 3-5 in the USA increased from 6.2% to 6.5% ( Figure 1 ). By contrast, the prevalence of stages 3-5 CKD in the UK decreased from 5.7% to 5.2% between 2003 and 2009-2010. 10 Patients with ESRD represent <0.1% of the total population in many high-income countries, but account for 1-2% of all health-care spending. 11 Estimates suggest that >US$1 trillion is spent on ESRD care worldwide. 12 The clinical and economic rationale for designing timely and appropriate health-system responses to limit progression of CKD to ESRD, therefore, is clear. [13] [14] [15] [16] This Review outlines the gaps in our knowledge as to which health-care interventions are most effective for early-stage (stages 1-3) CKD. We highlight the ongoing debate as to whether earlystage CKD is a normal indicator of the ageing process or is a genuine disease state. Finally, we discuss the optimum time to intervene, and what model of care to adopt.
Diagnosis of CKD
The first step in outlining an intervention strategy for CKD is to accurately define and identify those patients who have early-stage disease. The first guidelines for the diagnosis and treatment of CKD were published in 2002 by the National Kidney Foundation, a US voluntary health organization. 17 These guidelines were an important advancement in bringing CKD to the attention of policy makers. The National Kidney Foundation recommendations, referred to as the 'KDOQI' guidelines, were adopted by countries and institutions worldwide and form the basis of the CKD classification system ( Table 1) .
The most recent prevalence estimates (2007-2012) indicate that over 40 million people in the USA have CKD; approximately one-third of the US population aged >60 years is affected. 9 Interestingly, >95% of affected individuals in the USA have early-stage CKD, and a similar distribution across stages has been observed in a wide range of eGFR and urinary albumin excretion rate) and/or the clinical care in <5% of cases. 25 This finding implies that many of the diagnostic tests conducted during the initial evaluation of patients with CKD are redundant, and supports the economic argument for distinguishing between the diagnosis of early-stage CKD and the assessment of complications in patients with CKD stages 4 and 5.
Age-associated decline in renal function
The estimated high lifetime risk of CKD calls into question a distinction between early-stage CKD and normal age-associated decline in renal function. A reduction in renal blood flow and renal mass, as well as progressive glomerulosclerosis, are part of the normal ageing process, with eGFR typically falling by ~0.75 ml/min/1.73 m 2 per year from the age of 40 years. 27 This rate of progression seems nonlinear, with eGFR loss slowing below 45 ml/ min/1.73 m 2 among elderly patients. 28 Population studies have found that the majority of patients with CKD are aged >60 years, and that most of these patients do not exhibit marked albuminuria. 29, 30 Difficulties are, therefore, apparent in differentiating between age-associated loss of kidney function and renal disease. 31 Elderly patients with a given reduction in eGFR are less likely to progress to ESRD than are non-elderly patients with an equivalent reduction in eGFR. 28, 32 The role of the ageing process has long been recognized in other organ systems; for example, the natural decline in forced expiratory volume with age indicates premature or accelerated loss of respiratory function. 33 Meta-analyses of >1.5 million patients have identified that the risk of ESRD is almost equivalent between patients aged above or below 65 years of age with an eGFR 45-59 ml/min/1.73 m 2 and an albumin-tocreatinine ratio <1.13 mg/mmol. 34, 35 Although the interaction between renal function and proteinuria does seem to differ with age-potentially due to the competing risk of death-these data have been interpreted as evidence against the introduction of differing thresholds for defining CKD based on age. Furthermore, it has been argued that senescent changes in eGFR are caused by other disease processes, such as hypertension and diabetes mellitus, rather than a natural decline in renal function. 36, 37 The differing interpretations of these data on eGFR loss in the elderly underscore the need to consider eGFR trends as a part of the clinical assessment. Whether these changes in eGFR reflect intrinsic renal disease or normal ageing is unclear, but CKD and senility are associated with an elevated risk of morbidity and mortality in an additive fashion. 34 Many patients with CKD exhibit comorbidities. In the UK, ~64% of patients aged >65 years with CKD exhibit at least four additional morbidities, including prostate, respiratory, and cardiac diseases in men, and bone, joint, and mental health problems in women. 38 Although it is acknowledged that multi-morbidity imposes an increased need for health care, the risk factors for multi-morbidity are poorly defined. 39, 40 Further work is required to determine whether renal impairment in elderly patients is either associated with or causative of other conditions. Equations to estimate glomerular filtration rate The creatinine-based formulae used to estimate glomerular filtration rate (GFR) have other known limitations, in addition to the confounds of age-associated decline in renal function described above. 41, 42 These formulae were originally developed to identify patients with an eGFR ≤60 ml/min/1.73 m 2 at risk of renal failure, and are not sensitive for identification of CKD stages 1 or 2 ( Figure 3) . 43 In isolation, eGFR is of little value for earlystage CKD intervention efforts. Some clinicians have called for the removal of the first two stages of CKD from the KDOQI guidelines, 44 whereas others have proposed alternative methods to classify the early stages of CKD. 45 The MDRD study equation tends to underestimate the true GFR among individuals with normal kidney function, [46] [47] [48] [49] whereas the CKD-EPI equation tends to overestimate GFR in individuals with or at high risk of CKD. 50 These two equations only estimate the GFR within 30% of the actual value; the estimated values are even less accurate in 15.9% of cases using the CKD-EPI equation 51 and in 19.4% of cases using the MDRD equation. 52 Differences in sex and ethnicity should also be considered when evaluating GFR. 32, 44 Epidemiologic studies have used different eGFR formulae, which limits direct comparison of different studies owing to the varying level of accuracy of the different formulae among patients with a high eGFR. 9, 10, 29 Such studies have often relied upon point estimates of eGFR that might overstate prevalence rates. 9 A diagnosis of CKD should instead be made only after multiple estimates have been taken over several months. Moreover, not all studies consider the albumin excretion rate when estimating prevalence rates.
Cystatin C-derived eGFR equations
The limitations of creatinine-based GFR estimates have resulted in the investigation of other molecules, including β-trace protein 53 and cystatin C, as markers of renal function. 54 The latter protein provides a more accurate estimate of renal function than does β-trace protein, even among elderly patients, [55] [56] [57] especially when it is used in combination with measurements of serum creatinine. 58 Moreover, cystatin C-derived formulae function well at discriminating between high GFRs as compared with creatinine-based formulae. 26 The use of cystatin C-derived formulae is now recommended to confirm or exclude CKD in patients with mild reductions in eGFR (as assessed using creatinine-based estimates) and an albumin-to-creatinine ratio of <3mg/ mmol. 6, 26 This strategy might lead to future cost savings by reducing health-care use among patients who are wrongly diagnosed with CKD. An international standard reference for cystatin C measurement has now been agreed upon (ERM-DA47/IFCC), 59 but the assay is not yet widely available. Diagnostic accuracy might improve if uptake of the assay increases.
Albuminuria
Although urinary albumin excretion rates provide valuable diagnostic data, tests for albuminuria have limitations, such as poor test-retest reliability, 60, 61 further supporting the need to use more than one prognostic factor to define CKD. Measurements of albuminuria can vary depending on the type of assay (for example, monoclonal versus polyclonal antibody methods), 62 the sample collection method (for example, 24 h collection versus first morning void versus random spot sample), 63 and the sample storage procedure. 64 Furthermore, although standard thresholds for pathologic albumin excretion are used across sex and age, both factors might affect urinary albumin measurements. [65] [66] [67] Key points for clinical practice Estimates of GFR that do not incorporate cystatin C data are imprecise, and clinicians need to be aware of the strengths and limitations of such diagnostic tools. Primary care physicians (PCPs) should rely on their clinical judgement when evaluating individual patients with respect to eGFR trends and albuminuria. Although these two parameters jointly provide accurate predictive information about the risk of ESRD, 68, 69 clinicians should also consider the severity of comorbidities, family histories and vascular risk profiles. 70, 71 More work is needed to improve the sensitivity and specificity of eGFR formulae and other risk equations for identifying progressive CKD ( Table 2) .
Management of early CKD
The majority of patients with CKD do not progress to ESRD. Treatment of the entire CKD population is, The proteinuria measures were based on albumin:creatinine ratios from spot morning urine samples. The estimated glomerular filtration rates were calculated using the CKD-EPI creatinine formula. Stage 3 CKD corresponds to a glomerular filtration rate of 30-59 ml/min/1.73 m 2 . The error bars show the 95% confidence intervals. Data were obtained from the USRDS 2014 Annual Data Report. 9 The data reported here were supplied by the USRDS. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. Abbreviations: CKD, chronic kidney disease; USRDS, United States Renal Data System. therefore, neither clinically appropriate nor, given the global scale of the disease, economically feasible. Clinical care might improve if early-stage CKD with risk of progression to ESRD is differentiated from early-stage CKD that is unlikely to advance (Box 1). Interventional studies might also benefit from a selective definition of early-stage CKD. For example, the benefits of dietary salt restriction have not been conclusively established. 72 A post hoc analysis of the ONTARGET and TRANSCEND studies identified no renal benefit of dietary salt restriction among patients with early CKD. 73 Given the reported benefits of a low salt diet for patients with advanced renal failure, 74 it is possible that certain patients might be better suited than others to dietary salt restrictions.
The screening debate A systematic review of screening, monitoring and treating patients with CKD stages 1-3, commissioned by the US Preventive Services Task Force (USPSTF), questioned the clinical and economic value of screening both the general population and those at high risk of developing CKD. 75 This stance is supported by the American College of Physicians (ACP). 76 The USPSTF systematic review found no randomized controlled trials (RCTs) of "CKD screening in adults who were asymptomatic with or without recognized risk factors for CKD incidence, progression, or complications," and no RCTs of "monitoring adults with CKD stages 1 to 3 for worsening kidney function or damage. " 75 The position of the USPSTF and the ACP is not universally supported. In the UK, the National Institute for Health and Care Excellence (NICE) advocates targeted assessment for CKD in patients prescribed medications known to be nephrotoxic (for example, calcineurin inhibitors, NSAIDs and lithium), and in patients with diseases linked to CKD, such as T2DM. 26 The American Society of Nephrology (ASN) contends that universal screening for CKD is appropriate given the asymptomatic nature of mild-to-moderate CKD and the difficulties in performing an accurate clinical investigation. Although the ASN acknowledges the lack of support from RCTs for this position, the society proposes that early and improved blood pressure control might slow progressive loss of renal function and that improved awareness of CKD might be relevant during periods of hospitalization. 77 A systematic review concluded that screening for proteinuria might be cost-effective-defined as <US$50,000 per quality-adjusted life year gained-for patients with T2DM and/or hypertension. 78 The review also found that eGFR screening might be cost-effective in patients with T2DM. No studies of the cost-effectiveness of eGFR screening in patients with hypertension have been performed. 78 Treatment of early-stage CKD Some evidence suggests that lifestyle changes and the use of preventive medicines can reduce the risk of cardiovascular disease and possibly slow, halt, or even reverse CKD progression during the early stages of disease. 1, 79 The evidence collected thus far is generally of low quality, but provides some support for calorie-controlled diets, [80] [81] [82] [83] physical exercise, [84] [85] [86] and smoking cessation [87] [88] [89] predominantly in patients with T2DM that is comorbid with CKD. Most patients with CKD have comorbidities that are amen able to a systematic approach to prevention and early management, and many patients die from cardiovascular events or other causes before developing ESRD. 70, 90, 91 The pathophysiology of increased vascular risk evolves over the natural history of CKD, 92 and traditional risk factors for atherosclerosis have a proportionately greater impact on disease progression during early-stage CKD. In early-stage CKD, 93, 94 treatment with lipid-lowering agents reduces the risk of cardiovascular events despite a low association between LDL cholesterol and outcomes in patients with CKD stages 3-5. 95 Improved awareness of CKD as a risk factor for vascular disease could facilitate timely use of these agents alongside other interventions, such as blood pressure control. 96 RCTs of angiotensinconverting enzyme (ACE) inhibitors 97 and angiotensin II-receptor blockers (ARBs) 98, 99 have provided the strongest evidence of a treatment benefit among patients with early-stage CKD. These studies, however, focused on patients with diabetic renal disease in the presence of proteinuria, and the data to support the use of these agents for other causes of CKD are weak. 100 Nature Reviews | Nephrology The Chinese study used a sample of individuals from Beijing, 18 the Indian study used a sample from 13 academic and private medical centres located throughout the country, 19 and the Korean study used a sample from seven urban cities. 21 The other studies used nationally representative samples. For Japan, the prevalence estimate for stage 4 includes both stages 4 and 5 CKD. 20 All studies either sampled adults aged ≥18 years or ≥20 years, except for the Korean study which included adults aged ≥35 years. All studies used a version of the four-variable MDRD study equation to determine estimated glomerular filtration rate, except for the US study data, which used the CKD-EPI creatinine formula. The Chinese, 18 Korean, 21 Spanish, 22 and US 9 studies measured proteinuria using the spot morning urinary albumin:creatinine ratio. The remaining studies used a urine dipstick analysis for proteinuria. The Chinese study 18 also measured haematuria by dipstick test.
The rate of increase in the incidence of ESRD is slowing in some countries, including Australia, Canada, northern European countries, New Zealand and the USA, although these trends vary by subgroups, such as age and race. 101 The stabilization of these incidence rates might reflect improvements in cardiovascular risk management in the general population and among individuals with T2DM and/or hypertension, although this effect has yet to be shown conclusively.
Evidence gaps
The conflicting views of the ACP, ASN, NICE and USPSTF highlight the need for more RCTs to evaluate identification, screening, monitoring and treatment of early CKD. In the meantime, population health management could focus on the control of vascular risk factors and on the patients with CKD who are likely to progress to ESRD, and will subsequently place a burden on healthcare costs. 102, 103 Given the asymptomatic and insidious onset of CKD, research into new biomarkers and prognostic techniques is essential. [104] [105] Development of such assays is an active area of research, and new prediction models are regularly published. [105] [106] [107] [108] [109] [110] [111] Nevertheless, more work is needed to validate and refine these models. The findings across patient groups should be examined to determine how the data could be generalized: one model could be appropriate for one patient population in a particular geographic region, but it might be less accurate, or even lead to erroneous conclusions, when applied to other patient groups or populations.
Expanding the definition of early CKD must be considered in connection with the adverse outcomes associated with a reduced eGFR. 91 Two meta-analyses found that patients with hypertension and/or T2DM and with reductions in eGFR have an increased risk of ESRD and death compared with those with reduced eGFR but no hypertension or T2DM. 112, 113 In both studies, the risk of ESRD was markedly elevated when eGFRs dropped to <50 ml/min/1.73 m 2 , but the risk of death was increased at eGFRs <90 ml/min/1.73 m 2 . Although these data could be interpreted to support defining a mild reduction in renal function as part of a disease state, it is important to consider the difference in the threshold for the risk of death and ESRD. These findings also raise the question of population risk versus individual risk. Patients with early CKD but at low risk of ESRD still carry an elevated risk of other complications compared to the general population. 114 Screening patients for reductions in eGFR might not contribute meaningful prognostic information at an individual level with regard to ESRD risk. Small reductions in eGFR, however, can improve discrimination in models of cardiovascular risk, and the rate of change in eGFR might be a more effective predictor of risk, as compared to absolute values. 115, 116 Stage 1-2 CKD should possibly be assessed in association with cardiovascular risk rather than renal risk. This assessment might be particularly relevant when considering elderly patients with reduced measures of eGFR but no appreciable albuminuria. The risk of ESRD and death was associated with increased albuminuria in a linear manner in the two meta-analyses described above, 112, 113 further emphasizing the importance of albuminuria in defining the risk of CKD progression.
Models of CKD care
The Wagner chronic care model Some evidence suggests that the prevailing care strategy for CKD should comprise three phases (Figure 4) . Primary care management of vascular disease risk during early-stage CKD forms the first phase of the care strategy, which could involve exercise, dietary changes, smoking cessation, blood pressure control, glycaemic and lipid control and periodic monitoring of kidney health. The second phase could provide structured care to target comorbidities, such as anaemia, bone disease and secondary hyperparathyroidism, which develop in patients with CKD that progresses to stage 4-5. The final, third phase involves multidisciplinary, intensive care for patients transitioning to renal replacement therapy (CKD stage 5 and ESRD). 117, 118 Given the current distribution of CKD cases across stages 1-5 (Figures 1 and 2) , 9 the majority of patients with CKD would fall into the first phase of care described above. Consequently, the management of CKD could be The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. The four-variable MDRD study data were reported by Coresh et al. 29 Both studies used measures of albumin:creatinine ratios from spot morning urine samples. Stage 3 CKD corresponds to a glomerular filtration rate of 30-59 ml/ min/1.73 m
2
. The error bars show the 95% confidence intervals. The prevalence of stage 5 CKD was not estimated with the MDRD equation in this study 29 as it was deemed that "estimates of this stage are likely to be unreliable due to the small number of individuals and the likelihood that many of these individuals are ill or receiving dialysis and would have a low response rate." 29 Abbreviations: CKD, chronic kidney disease; USRDS, United States Renal Data System. reconceptualized as a part of primary care. 119 The adoption of an integrated care approach might help to coordinate the continuum of care for patients with CKD. 120 This care strategy would be aligned with the chronic care model developed by Edward H. Wagner, which consists of six core parts: community resources and policies; health-care organization; self-management support; delivery system design; decision support; and clinical information systems. [121] [122] [123] [124] The implementation of such changes in clinical practice is needed as the prevalence rates of T2DM and hypertension are expected to increase and will add to the global burden of CKD. [125] [126] [127] A shift to a primary care model might enable nephrologists and other specialists to focus on patients with primary kidney disease, progressive CKD and ESRD.
For all patients with CKD, PCPs should check for drug interactions, environmental toxins, and contrast dyes that might cause acute kidney injury. These factors could be monitored with the help of information technology systems, which could, for example, alert physicians to potentially harmful drug combinations. Some prescription and over-the-counter medicines, such as NSAIDs, can precipitate acute kidney injury in patients with CKD, and can accelerate progression of CKD. [128] [129] [130] Numerous studies have highlighted the shortcomings of primary care for patients with CKD (Table 2) . Notably, there is low awareness of the KDOQI guidelines and diagnostic techniques, [131] [132] [133] [134] [135] [136] suboptimal prescribing and management for patients with T2DM and/or hypertension, 9, [136] [137] [138] [139] [140] and poor recognition of the known risk factors for CKD. 131 A survey of 470 US-based PCPs found that only 35% had "adequate knowledge" of CKD based on responses to 27 questions. 141 For each 10-year increase in the age of the PCP, the odds of having adequate knowledge decreased by 26%. 141 Another study found that only 19% of family practitioners and 33% of general internists in the USA followed the KDOQI guidelines for the laboratory and radiological evaluation of patients with CKD. 133 In a study commissioned by the US National Kidney Disease Education Program, approximately onethird and one-quarter of US-based PCPs did not recognize family history and African-American ethnicity as risk factors for CKD, respectively. 131 High awareness that T2DM and hypertension are predictors of CKD was, however, identified. 127 These three surveys 131, 133, 141 were voluntary and had low response rates, ranging from 7.6% to 32.4%. The participants of these studies might not be representative of the general PCP population, and it is possible that these findings-which already point to substantial room for improvement-overstate the quality of CKD care ( Table 2) .
The secondary care model Timely involvement of renal specialists is required to improve health outcomes for patients with progressive CKD. Payers, however, which are any groups, other than patients, that are responsible for funding or reimbursing the cost of health care, want to avoid unnecessary referral patterns that could deplete resources. Depending on the country, the term 'payer' might refer to private or public insurers, employers, or other third-party payers.
A systematic review of the clinical and costeffectiveness of early versus late (or no) referral to a nephrologist found that an early referral is associated with better health outcomes and might be more costeffective than late referral. 142 RCTs that provide data on the clinical effectiveness of early referral strategies were not identified. Only two studies included patients who were in the predialysis stage, and insufficient data were available on the natural history of CKD and the costs and effects of early referral. These data highlight the requirement for long-term observational studies of patients with early-stage CKD to enhance delineation of disease progression and the incidence of cardiovascular events in patients with and without associated health conditions, such as T2DM, pre-existing cardiovascular disease, albuminuria or proteinuria. Finally, the authors of the systematic review suggested that the substantial costs of early referral might be unaffordable for health-care systems, even if early referral is cost-effective in the long term. Further research is needed to evaluate the costeffectiveness of improved primary care for patients with early-stage CKD.
Early identification of CKD in the UK is financially incentivized in primary care, but some PCPs express concern as to whether early CKD is a genuine disease state across all ages. 143 In geographical areas where patients are not correctly identified on CKD registers, cardiovascular management is suboptimal, with worse control of blood pressure and cholesterol levels, compared to those patients included on CKD registers. 144 A transition to a primary care model should be a universal decision, unlike the development of current guidelines that have been driven by secondary care providers. 145 
Integrated care pathways for CKD
A unified strategy for patients across health-care providers and payers might improve overall outcomes (Box 2). Models of CKD care should be evaluated in terms of value for money, and there must be an understanding as to what approaches achieve a reliable service delivery to high-risk populations. CKD can provide a useful case study of how to enact a primary care model that is oriented towards public health and that is patient-centred.
CKD care pathways in the USA Despite the fragmentation of the US health system, improvements in CKD care have been observed in public health-care organizations (for example, the Indian Health Service [146] [147] [148] and Veterans Health Administration 149 ) and private health-care organizations (for example, Kaiser Permanente 150, 151 ). In the 1990s, the Indian Health Service employed various primary care strategies to combat the growing burden of T2DM and hypertension among American Indians and Alaskan Natives. These strategies included the promotion of T2DM awareness and lifestyle changes for patients (for example, healthy eating), the routine screening for CKD as part of primary care, the continued education of providers (for example, PCPs, advanced practice nurses, and pharmacists), the improvement of pharmacologic care for patients with T2DM and hypertension, and the greater use of diabetes registries. [146] [147] [148] By 2006-2007, >80% of patients in the Indian Health Service with comorbid hypertension and diabetes mellitus were receiving an ACE inhibitor or ARB. 147 Between 1997 and 2007, the mean haemoglobin A1c and LDL cholesterol levels decreased from 8.65% to 7.85% and from 3.1 mmol/l (120 mg/dl) to 2.5 mmol/l (96 mg/dl), respectively. 148 The age-adjusted incidence of ESRD among American Indians with diabetes mellitus decreased by 31% (80.4 per 10,000 diabetic patients to 55.8 per 10,000 diabetic patients) between 1990 and 2001. 146 The care strategies used by the Indian Health Service have demonstrated that a system-wide approach, even in an underfunded system, can produce notable benefits in terms of cardiovascular and renal health outcomes.
Kaiser Permanente of Southern California is a vertically-integrated health maintenance organization that has deviated from the KDOQI guidelines. 151 This organization instead applies a composite risk assessment to target patients whose conditions are expected to worsen, and it uses automated information technology systems that suggest treatment options based on inputted patient information. The Hawaiian network of Kaiser Permanente has also started to provide care to patients with CKD based on risk stratification, and has found that this approach is associated with a statistically significant reduction in disease progression. 150 CKD care pathways in the UK Growing integration between primary and secondary care is evident in the UK. A study performed in 2003-which preceded automated eGFR reporting-reviewed the electronic primary care records of >130,000 patients and found a high rate of undiagnosed CKD, with <20% of patients with an eGFR <30 ml/min/1.73 m 2 being coded as having renal disease. 152 Although automated eGFR reporting has improved the detection of CKD in primary care and has increased referral rates, this study suggests that it is possible to alert PCPs about missed opportunities for preventive prescribing.
A model of CKD management similar to that introduced by Kaiser Permanente 150 was initiated between 2003 and 2006 in the West Midlands, UK. The initial results show that patient outcomes have improved as a result of this care strategy, with a reduction in the populationadjusted incidence of renal replacement therapy. 153 Another study in West Lincolnshire, UK, evaluated the health outcomes of patients with CKD stages 4-5 treated in primary care with a disease management programme, which was similar to a secondary care multidisciplinary clinic. The programme improved health outcomes and slowed the reduction in eGFR over a 9-month period. 154 Intensive, target-driven disease management programmes have produced positive outcomes in the management of T2DM, 155 and scope exists for such approaches to be applied to the care of patients with CKD.
Other international experiences
Other countries, including Australia and Canada, are transitioning towards primary care models for the management of CKD in the general population. Similar to the Indian Health Service, Australia has relied on community-based CKD care for the population of the Tiwi Islands, an aboriginal community. 156 The model of the Tiwi Islands focuses on controlling blood pressure and lipid levels, and health education, with the aim to improve cardiovascular health and preserve renal function. The published data indicate that this strategy has markedly improved cardiovascular and renal health outcomes in this population. 156 These international experiences suggest that a holistic care model can be successfully applied across different types of health systems. Health-economic modelling of CKD care
As previously described, physicians should consider the limitations of population-based equations to estimate GFR and instead evaluate individual patient characteristics when predicting disease risk and developing treatment plans. Structured, early CKD intervention programmes can form the basis for such personalized care. Given the heterogeneity of patients with early-stage CKD, and the variable risks in different populations, clarity as to the appropriate scope and impact of such programmes is needed. Health-care providers, payers and the general public should be made aware of the cost-effectiveness of investing in CKD intervention programmes (Box 3). Systems modelling is an inexpensive method to study the effects of different interventions on chronic disease outcomes and costs. [157] [158] [159] Software can be used to design comprehensive care models in patient populations and observe the burdens of T2DM, hypertension, CKD and ESRD over time. 160 This method of modelling allows for sensitivity analyses to test the degree of uncertainty around the model assumptions. These analyses can provide an indication of the reliability and strength of the results, and highlight areas where further research is needed.
Alongside systems modelling, long-term prospective cohort studies are required to interpret the clinical and economic value of different intervention strategies from a payer or societal perspective. Ideally, these studies should incorporate RCTs of CKD treatments into their design. Furthermore, economic analyses should be conducted in parallel with outcome evaluations. Notably, the Nord-Trøndelag Health Study (HUNT) performed in Norway, 161 the Kaiser Permanente 151 and West Midlands studies, 153 and the majority of CKD quality improvement studies do not consider health-care costs. Incorporating health-economic evaluations into these population-based studies would generate useful evidence to guide approaches to CKD care. Relevant stakeholders should also establish registries to monitor the long-term health and cost effects of different care pathways and the timing of care initiation.
Conclusions
Insufficient evidence has been generated regarding the clinical and economic benefits of early CKD intervention, especially in comparison to other diseases, such as T2DM and stroke. To date, no RCTs have assessed the clinical and economic outcomes of early intervention strategies, and comprehensive patient-level data are not readily accessible. Early diagnosis, treatment and management of CKD could alter the natural history of this disease and generate substantial cost savings. Improved understanding of the merits and disadvantages of different care approaches for CKD and knowledge as to where evidence is lacking are essential to improve health outcomes and minimize expenditure.
CKD, like many chronic conditions, can be considered a broad indicator of overall health. Patients with mild-to-moderate reductions in eGFR often have comorbidities that are more relevant to their current and future well-being than is their CKD diagnosis. 162 These comorbidities should remain the focus of treatment and management, as a low proportion of patients who are diagnosed with CKD will develop ESRD.
The difficulty for PCPs and nephrologists to identify patients with progressive CKD has weakened the effectiveness of early interventions. New biomarkers that might improve the detection and prognosis of CKD are becoming increasingly available, 163 but it is unlikely that any 'magic bullet' will fully address the disease burden of CKD. A unified care strategy across health-care providers and payers should be promoted. This assertion holds true for CKD, a particularly complex disease that involves many health-care providers over the lifetime of a patient, but also applies to other chronic illnesses.
Box 3 | Workforce, ICT, and other strategies to improve care for early-stage CKD Workforce ■ Motivated and educated workforce and patient population ■ Easy access to laboratory monitoring ■ Specialist nursing staff to support patient understanding of the disease ■ Financially viable secondary care renal services for a potentially smaller but very ill patient population PCP-specialist interface ■ Multi-specialty clinics in primary care to support PCP education and patient care ■ Defined referral and discharge criteria for secondary care
Role of ICT and decision-support systems ■ Integration of primary and secondary care records ■ Accessible results reported to patients in any location ■ Automated analysis of eGFR and/or trends in proteinuria ■ Incorporation of validated predictive models for ESRD into laboratory reports ■ Electronic prescribing linked to biochemical results
Health-economic impact and health-system financing ■ Economic analyses built into all studies of CKD screening and treatment ■ Financial incentives balanced towards prevention of progression to ESRD ■ Establishment of CKD registries to permit health-economic analyses
Leadership, governance, and role of national and international organizations ■ International, evidence-based accordance between national and international bodies regarding CKD screening and treatment ■ Increased data sharing between health systems of epidemiologic trends in CKD ■ Strong patient representation in all organizations Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ICT, information and communications technology; PCP, primary care physician.
